Curing Death
  Recent News |  Archives |  Tags |  About |  Newsletter |  Submit News |  Advertise With Us |  Subscribe to CuringDeath.com RSS Fee Subscribe
New Articles
Scientists can now differentiate between healthy cells and cancer cells 1/6/2009

'Relocation' plan of metastatic cancer cells uncovered 1/6/2009

Genetic variation may lead to early cardiovascular disease 1/5/2009

Scientists closing the zap on dengue fever 1/4/2009

Dormant cancer cells rely on cellular self-cannibalization to survive 1/4/2009

Toxicity mechanism identified for Parkinson's disease 1/4/2009

Molecular imaging enables earlier, individualized treatment of thyroid cancer 1/3/2009

Arousal frequency in heart failure found to be a unique sleep problem 1/3/2009

Researchers engineer pancreatic cell transplants to evade immune response 1/2/2009

A new light on the anti-tumor mechanisms of Scutellaria barbata 1/2/2009

Few DNA repair genes maintain association with cancer in field synopsis 1/2/2009

Scientists isolate genes that made 1918 flu lethal 1/2/2009

Grape-seed extract kills laboratory leukemia cells, proving value of natural compounds 1/1/2009

In lung cancer, silencing one crucial gene disrupts normal functioning of genome 1/1/2009

Scientists pull protein's tail to curtail cancer 1/1/2009

Researchers ID molecule linked to aggressive cancer growth, spread (11/16/2008)

Tags:
metastasis, cancer

Researchers at the University of Michigan Comprehensive Cancer Center have found a genetic marker that controls an enzyme present in aggressive and metastatic cancer. The study suggests an absence of microRNA-101 is related to high expression of the protein EZH2, which was previously shown to be active in metastatic cancers. MicroRNA's are molecules that help regulate gene expression. miR-101 is one of few miRNA's shown to play such an important role in the development of cancer.

In this study, the researchers found miR-101 is significantly underexpressed in a variety of cancers, including prostate and breast cancer. Essentially, the researchers believe that miR-101 suppresses the EZH2 protein. When miR-101 is lost in cancer, EZH2 expression is uncontrolled, and that haywire in-gene expression leads to more aggressive cancer growth.

Implications: The findings suggest that loss of miR-101 could potentially be used as a marker of aggressive or metastatic cancer. Replacement of miR-101 in cancers could also be developed as a future cancer treatment.

Study details: The study will be published online in the journal Science on Nov. 13. It was led by Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and investigator of the Howard Hughes Medical Institute.

Note: This story has been adapted from a news release issued by the University of Michigan Health System

Bankruptcy - Debt Consolidation - Credit Card Consolidation - Loans

Post Comments:

Search

  Archives |  Submit News |  Advertise With Us |  Contact Us |  Links
All contents © 2000 - 2010 Web Doodle, LLC. All rights reserved.
Web Doodle, LLC does not provide medical advice, diagnosis or treatment. Please read our disclaimer